RAVULIZUMAB FOR AHUS

Ravulizumab has not featured in an aHUS alliance news item heading before. Ravulizumab has been watched by the alliance from its appearance firstly as ALXN1210. It has been a promising…

SPOTLIGHT ON RAVULIZUMAB 4- SIDE EFFECTS

Article No. 320 19 February 2020   Continuing in the series of news blogs about Ravulizumab, which so far has covered dosing, special patient groups and developments, here the spotlight…

AHUS PATIENTS ON RAVULIZUMAB- WE NEED YOUR HELP.

…transitioned to ravulizumab from eculizumab after long term use; 2. transitioned to ravulizumab following an initial three months of eculizumab protocol 3. received ravulizumab treatment only. For each of those…

SPOTLIGHT ON RAVULIZUMAB 1- DOSING

…a spotlight will be shone on a number of basic facts about the use of Ravulizumab. Ravulizumab ( trade name Ultomiris) is indicated for : – adults with PNH –…

SPOTLIGHT ON RAVULIZUMAB 3- DEVELOPMENTS

…but eculizumab remains by far its biggest seller growing by nearly $400 million in the year. But last year also saw sales of its newer version Ravulizumab -cwvz . $338.9…

10/18/19- FDA DECIDES

…transition of treatment for PNH patients is repeated, probably all aHUS patients needing treatment in the USA will be receiving Ravulizumab. The active ingredient of Ravulizumab is eculizumab and it…

AHUS COMMUNITY ANSWERS THE CALL

…authentic and authoritative case to healthcare decision-makers that : “ From the evidence provided by those with experience of both eculizumab and ravulizumab treatments patients see ravulizumab as a positive…

2020 ATYPICAL HUS THERAPEUTIC DRUG OVERVIEW

…organs, or those where the body’s immune system has cascaded into an over-activated response. We’re heartened by approval of a second therapeutic drug (ravulizumab) to treat atypical HUS (eculizumab was…